10/25/2021 – In 2006, the market was excited about Pfizer’s (PFE) new inhalable insulin, Exubera. What patient wouldn’t want to inhale insulin rather than inject with scary needles? Never mind that 1) the device was bulky, 2) the dosing inflexible, 3) the price exorbitant, 4) the requirement for pulmonary function tests was expensive and burdensome,… Read More Entasis Phase 3 Results: More evidence market makers do not understand clinical pharmacotherapy.

10/13/2021- Entasis Therapeutics (ETTX) is a development stage pharmaceutical company which specializes in antibiotics and currently has 4 novel drugs in their pipeline. Two of their drugs are in Phase 1 and the other two are currently in Phase 3 with results expected late 2021 or early 2022. Sulbactam-Durlobactam is a semi- novel treatment for… Read More Entasis Therapeutics: Is a Moonshot Imminent?

12/9/2017: On 12/4/2017, Ra Pharmaceuticals (RARX) reported favorable interim results for its ongoing Phase II clinic study of their paroxysmal nocturnal hematuria (PNH) treatment, RA101495.  The market quickly rewarded their stock with a 44% decline over 2 days. So what gives? Why would the market punish Ra Pharmaceuticals so severely for what the company considered… Read More Ra Pharmaceuticals: Fall before the Rise.

Welcome to PhreedomRX! I’ve been working in the healthcare field for over a decade. During that time, I’ve always  enjoyed keeping up on the latest news and developments in the industry. However, with nearly every article I’ve read over the years, the same thought kept occurring. “This author doesn’t understand the subject they are reporting… Read More Welcome